An interventional study of Prostate cancer screening decision in Prostate Cancer, sponsored by Xijing Hospital. Enrolling by invitation at 9 sites in China. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-30.
Sponsored by Xijing Hospital · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Prostatic Neoplasms by Xijing Hospital — 10 open to participants now, 10 under way, none of them phase 3. Prostatic Neoplasms · Xijing Hospital.
Among the 10 studies in Prostatic Neoplasms by Xijing Hospital, this one is one of 5 that started in 2021, is one of 3 with no phase, and was the 3rd registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →10 of the 10 studies in Prostatic Neoplasms by Xijing Hospital are open now, in 2 countries. Recruiting first, the newest first:
Xijing Hospital · Sites in China
Ages 18+ · Men only
Xijing Hospital · Sites in China
Ages 18–100 · Men only
Xijing Hospital · Sites in China
Ages 18–75 · Healthy volunteers
Xijing Hospital · Sites in China
Ages 18–75 · Men only
Xijing Hospital · Sites in China
Ages 40–90 · Men only · Healthy volunteers
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,600 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 190 across the 4 interventional studies, 1,000 across the 6 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
Xijing Hospital is the lead sponsor of 475 studies on the registry; 158 are open to participants now.
4 of the studies in Prostatic Neoplasms by Xijing Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06604130Xijing HospitalPlasma Exosome RNA to Diagnose Prostate Cancer | 2026-12-31 |
| NCT07492927Xijing HospitalPlasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer | 2026-12-31 |
| NCT06914427Xijing HospitalPET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique | 2027-03-01 |
| NCT07553754Xijing HospitalPlasma Exosomal RNA Signature for Prostate Cancer Bone Metastasis | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 10 studies in Prostatic Neoplasms by Xijing Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the present study is to investigate a RNA combination to diagnose prostate cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: Prostate cancer screening decision
The subjects would receive serum PSA test.
The diagnostic efficacy of plasma exo-RNA panel alone in diagnosing PCa
The primary outcome is to investigate a plasma-exosome RNA panel in diagnosing prostate cancer and evaluate its sensitivity and specificity in diagnosing PCa. Descriptive statistics were calculated and presented as the frequency (percentage) for categorical variables, the mean (standard deviation) for continuous variables with a normal distribution, and the median (quartile) for continuous variables with a skewed distribution. Two-sample t-tests were used to assess continuous variables with a normal distribution, and the Wilcoxon signed-rank test was used to assess continuous variables with a skewed distribution. The Mann-Whitney U test was used to compare means from two samples. The correlation between two samples was analyzed by Spearman's ρ test. The receiver operating characteristic (ROC) curve was used to determine the cutoff value of exo-RNA panel for diagnosing patients with PCa.
Time frame: The time of prostate biopsy and after 6 months follow-up
Diagnostic efficacy of plasma exo-RNA panel in diagnosing csPCa, insignPCa and its comparison with other imaging methods or blood tests
The secondary outcome is to evaluate the positive predictive value (PPV), negative predictive value (NPV) and accuracy of exo-RNA panel in detection of PCa; to evaluate the perforamce of exo-RNA panel in identifying grade group 2 (GG2) or higher clinically significant prostate cancer (csPCa) tumors and compare the diagnostic performance of the plasma-exosome RNA panel with other imaging methods or blood tests in identifying prostate cancer patients; Whether the exo-RNA panel could predict the PCa patients with higher Gleason score (GS). The comparison between diagnostic performance of exo-RNA panel and other imaging or blood tests is performed in ROC curves. The ICC analysis was performed by reliability analysis. All statistical analyses were conducted using IBM SPSS statistics software, version 23.0 (IBM, Inc., Chicago, IL, USA) and GraphPad Prism software, version 8.0 (GraphPad Software, Inc., La Jolla, CA, USA).
Time frame: The time of prostate biopsy and after 6 months follow-up
Plan to share: Undecided — The subjects may not disclose their IPD totally or partly.
No publications or documents are linked to this record.
Started Mar 2021 (actual). Primary completion is estimated for Dec 2026, 69 months after the start.
Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 69 months is above that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.